Phase IB study of cabozantinib in patients with relapsed and/or refractory multiple myeloma

Nikoletta Lendvai; Andrew J. Yee; Ioanna Tsakos; Aeri Alexander; Sean M. Devlin; Hani Hassoun; Neha Korde; Alexander M. Lesokhin; Heather Landau; Sham Mailankody; Guenther Koehne; David J. Chung; Ola Landgren; Noopur S. Raje; Sergio Giralt

doi:10.1182/blood-2016-01-694786

Phase IB study of cabozantinib in patients with relapsed and/or refractory multiple myeloma

Nikoletta Lendvai, Andrew J. Yee, Ioanna Tsakos, Aeri Alexander, Sean M. Devlin, Hani Hassoun, Neha Korde, Alexander M. Lesokhin, Heather Landau, Sham Mailankody, Guenther Koehne, David J. Chung, Ola Landgren, Noopur S. Raje, Sergio Giralt

Miami Cancer Institute

Research output: Contribution to journal › Article › peer-review

Original language	American English
Journal	Blood
Volume	127
DOIs	https://doi.org/10.1182/blood-2016-01-694786
State	Published - May 12 2016

Disciplines

Medicine and Health Sciences
Immunology and Infectious Disease

Access to Document

10.1182/blood-2016-01-694786License: Unspecified

Cite this

@article{d58be7fbbae94216a9ed95b6ec686261,

title = "Phase IB study of cabozantinib in patients with relapsed and/or refractory multiple myeloma",

author = "Nikoletta Lendvai and Yee, {Andrew J.} and Ioanna Tsakos and Aeri Alexander and Devlin, {Sean M.} and Hani Hassoun and Neha Korde and Lesokhin, {Alexander M.} and Heather Landau and Sham Mailankody and Guenther Koehne and Chung, {David J.} and Ola Landgren and Raje, {Noopur S.} and Sergio Giralt",

note = "To the editor: Despite the introduction of proteasome inhibitors and immunomodulatory drugs followed by autologous stem cell transplant, most patients with multiple myeloma (MM) will have disease recurrence after primary therapy. Thus, agents with different mechanisms of action and different",

year = "2016",

month = may,

day = "12",

doi = "10.1182/blood-2016-01-694786",

language = "American English",

volume = "127",

journal = "Blood",

}

TY - JOUR

T1 - Phase IB study of cabozantinib in patients with relapsed and/or refractory multiple myeloma

AU - Lendvai, Nikoletta

AU - Yee, Andrew J.

AU - Tsakos, Ioanna

AU - Alexander, Aeri

AU - Devlin, Sean M.

AU - Hassoun, Hani

AU - Korde, Neha

AU - Lesokhin, Alexander M.

AU - Landau, Heather

AU - Mailankody, Sham

AU - Koehne, Guenther

AU - Chung, David J.

AU - Landgren, Ola

AU - Raje, Noopur S.

AU - Giralt, Sergio

N1 - To the editor: Despite the introduction of proteasome inhibitors and immunomodulatory drugs followed by autologous stem cell transplant, most patients with multiple myeloma (MM) will have disease recurrence after primary therapy. Thus, agents with different mechanisms of action and different

PY - 2016/5/12

Y1 - 2016/5/12

UR - http://www.bloodjournal.org/content/127/19/2355?sso-checked=true

U2 - 10.1182/blood-2016-01-694786

DO - 10.1182/blood-2016-01-694786

M3 - Article

VL - 127

JO - Blood

JF - Blood

ER -

Phase IB study of cabozantinib in patients with relapsed and/or refractory multiple myeloma

Disciplines

Access to Document

Other files and links

Cite this